Halozyme, Inc. vs. Alteogen Inc.

Explore the PTAB proceeding IPR2026-00176 filed by Halozyme, Inc. on 2025-12-10. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2026-00176

Filing Date

2025-12-10

Accorded Filing Date

2025-12-10

Institution Decision Date

2026-05-15

Last Modified Date

2026-07-07

Proceeding Type

IPR

Termination Date

2026-05-15

Trial Status

Institution Denied

Parties & Counsel

Petitioner

Halozyme, Inc.

Represented By

Rosato, Michaelet al

Patent Owner / Respondent

Alteogen Inc.

Represented By

Feldstein, Market al

Tribunal & Venue

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Patent Information

1 Patent Involved

Respondent Application Number 17907538

Respondent Patent Number 12221638

External Links

Espacenet

Google Patents

Respondent Inventor Soon Jae PARK et al

Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Address and Attorney/Agent Information

55 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name SUGHRUE MION, PLLC

Customer Number 23373

Address 2000 PENNSYLVANIA AVENUE, N.W., SUITE 9000, WASHINGTON, DC, 20006, UNITED STATES

Attorney / Agent Information

Reg #	Name	Phone
25426	Alan Kasper	202-293-7060
32156	William Mandir	202-293-7060
32197	Mark Boland	202-293-7060
32607	John Callahan	202-663-7387
32765	Brett Sylvester	202-293-7060
32778	Brian Hannon	202-293-7060
33725	Bruce Kramer	202-663-7951
36787	Michael Dzwonczyk	202-293-7060
38584	John Rabena	202-663-7472
39283	J Lytle Jr	202-293-7060
40766	Carl Pellegrini	202-663-7485
41157	Christopher Lipp	202-663-7425
41239	Susan Pan	202-663-7373
43042	Ellen Smith	202-293-7060
43078	Raja Saliba	202-663-7468
46027	John Bird	202-775-7584
47121	Keiko Takagi	202-293-7060
53892	Sunhee Lee	202-775-7588
54666	Andrew Taska	202-857-3217
55154	David Emery	301-299-2385
57070	Thomas Sexton	202-663-7422
57426	Hui Wauters	202-663-7430
58308	Kevin Kunzendorf	202-663-7375
60447	Soumya Panda	703-412-7053
60719	Peter Park	202-857-3358
61124	Seok Won Lee	202-293-7060
61444	Michael Raucci	202-293-7060
61973	Fadi Kiblawi	202-663-7386
62499	Ebenesar Thomas	202-857-3235
62812	Ian Barras	202-663-7906
65399	Nelson Runkle	202-293-7060
65471	Andrew Yeretsky	202-663-7440
68485	Il Nam Koh	202-775-7508
68517	Brian Repper	703-836-6400
70362	Thomas Negley	863-207-22201
71831	Christian Lapense Ii	202-293-7060
72208	Maki Saitoh	202-663-7958
72682	Joshua Dean	202-663-7470
72943	Tyler Del Rosario	202-857-2257
73409	Aiyda Ghahramani	202-663-7429
73454	Daegunn Jei	202-731-3882
73602	Yejin Kim	202-663-7433
74061	Sujin Park	202-775-7524
74833	Hyunseok Park	202-663-7434
75180	Lawrence Rachuba Ii	202-663-7945
77233	Gleb Savich	919-448-4242
78445	Young Sun Kwon	202-775-7513
78891	Javier Liceaga	202-293-7060
78937	Jae Seok Ahn	202-663-7367
80511	Stephanie Kalen	202-857-2247
80625	Emmanuel Psihountas	913-850-0023
80904	Paul Smith	202-293-7060
81698	Michael Tomczak	815-690-2338
82017	Derek True	202-663-7931
L1355	Janvi Shah	202-293-7060

Proceeding Documents

Notice: refund approved NOTICE

2026-07-07 FILING PARTY: BOARD

Download

Petitioner's Request for Refund OTHER

2026-07-01 FILING PARTY: PETITIONER

Download

Institution Decision: Deny DECISION

2026-05-15 FILING PARTY: BOARD

Download

Director Discretionary Decision: Refer RESPONSE

2026-04-01 FILING PARTY: BOARD

Download

2012

Rodriguez et al. 2010 Exhibit

2026-03-16 FILING PARTY: PATENT OWNER

Download

Halozyme, Inc. vs. Alteogen Inc.

Proceeding Overview

Parties & Counsel

Petitioner

Halozyme, Inc.

Represented By

Patent Owner / Respondent

Alteogen Inc.

Represented By

Tribunal & Venue

Patent Information

Address and Attorney/Agent Information

Power of Attorney & Correspondence

Attorney / Agent Information

Proceeding Documents

Notice: refund approved NOTICE

Petitioner's Request for Refund OTHER

Institution Decision: Deny DECISION

Director Discretionary Decision: Refer RESPONSE

Rodriguez et al. 2010 Exhibit

Excerpts from EP4269578 Prosecution History Exhibit

EP4421168A2 Exhibit

EP4421168_EPO Examination Notice (5 Mar 2026) Exhibit

Excerpts from EP3760715 Opposition File History Exhibit

WO2019222435A1 Exhibit

Aghamohseni et al. 2017 Exhibit

US Provisional 61068667 Exhibit

Clark 2004 Exhibit

Lindstrom 2020 Exhibit

Excerpts from EP4269578 Opposition File History Exhibit

EP3760715B1 Exhibit

Patent Owner's Preliminary Response POPR

Petitioner's Opposition to Patent Owner's Discretionary Denial Request RESPONSE

EP4269578 Exhibit

Excerpts from Prosecution History of U.S. Appl. No. 17/907,538 Exhibit

Patent Owner's Request for Discretionary Denial RESPONSE

Patent Owner's Mandatory Notice NOTICE

Patent Owner's Power of Attorney NOTICE

Petitioner's Updated Mandatory Notices NOTICE

NOTICE OF FILING DATE ACCORDED TO PETITION AND TIME FOR FILING PATENT OWNER PRELIMINARY RESPONSE NOTICE

“Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcut Exhibit

“Protein Glycosylation Control in Mammalian Cell Culture: Past Precedents a Exhibit

“Optimizing CHO Cell Culture Conditions” to Christopher A. Sellick, Arfa R. Exhibit

“Recombinant Proteins for Industrial versus Pharmaceutical Purposes: Exhibit

Gowtham YK, Saski CA, Harcum SW. “Low glucose concentrations within typical Exhibit

“Production platforms for biotherapeutic glycoproteins. Occurrence, impact, Exhibit

“Human cell lines for biopharmaceutical manufacturing: history, status, and Exhibit

U.S. Patent No. 8,187,855 to David Baker and Louis H. Bookbinder (“Baker”) Exhibit

International Patent Publication WO2013/102144 to Ge Wei, Michael H. Shepar Exhibit

“N-Glycosylation and enzymatic activity of the rHuPH20 expressed in Chinese Exhibit

Declaration of Michael Butler, Ph.D. Exhibit

International Patent Publication WO2017/011598 to Jonathan Zmuda and Chao Exhibit

U.S. Patent No. 12,221,638 to Park (“the ’638 patent”) Exhibit

Notice: Power of Attorney NOTICE

“Effects of Culture Conditions on N-Glycolylneuraminic Acid (Neu5Gc) Conten Exhibit

“A recombinant human enzyme for enhanced interstitial transport of therapeu Exhibit

“ENHANZE® drug delivery technology: a novel approach to subcutaneous admini Exhibit

“NIST Interlaboratory Study on Glycosylation Analysis of Monoclonal Antibod Exhibit

“Optimal and consistent protein glycosylation in mammalian cell culture” to Exhibit

“Systematic development of temperature shift strategies for Chinese hamster Exhibit

Invitrogen CELL CULTURE BASICS Handbook Exhibit

U.S. Patent Application Publication US20210155913A1 to Park Exhibit

Gibco CD CHO Medium User Guide Exhibit

“Exploring the effect of mild hypothermia on CHO cell productivity” Exhibit

“Biphasic cultivation strategy to avoid Epo-Fc aggregation and optimize pro Exhibit

Petition: as filed PETITION

“Attaining High Transient Titers in CHO Cells” Liu, Chao Yan, Exhibit

EP3037529 to Ge Wei, Krishnasamy Paneerselvam, Gregory I. Frost, and Louis Exhibit

Curriculum Vitae of Michael Butler, Ph.D. Exhibit

“The Combined Effect of Sodium Butyrate and Low Culture Temperature on the Exhibit

International Patent Publication No. WO2020/022791 to Park Exhibit

“Mammalian cell culture for production of recombinant proteins: A review of Exhibit

Excerpted prosecution history of U.S. Appl. No. 17/907,538 Exhibit

Butler M, Meneses-Acosta A. Recent advances in technology supporting biopha Exhibit

“Miniaturized Integrated Platform for Electrical and Optical Monitoring of Exhibit

“Hyaluronidase: An overview of its properties, applications, and side effec Exhibit

“Process Parameter Shifting: Part I. Effect of DOT, pH, and Temperature on Exhibit